Remedy with Zervyteg (MaaT013) generated encouraging outcomes and demonstrated an appropriate security profile in sufferers with acute graft-vs-host illness that impacts the...
Amongst sufferers within the relapsed/refractory and treatment-naive settings with Bruton tyrosine kinase inhibitor–naive persistent lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL), Jaypirca...
